China News Service, March 14. According to the website of the State Intellectual Property Office on the 14th, recently, the World Intellectual Property Organization (WIPO) held an online press conference to release the "Patent Situation Report on COVID-19 Related Vaccines and Therapeutics".
According to the report, China is the largest source of patent applications related to COVID-19 vaccines and treatments.
At the meeting, the directors-general of WIPO, the World Health Organization and the World Trade Organization delivered speeches respectively. Representatives of relevant intellectual property offices, international organizations, scientific research institutes and other institutions, including our office, discussed the scientific research in the fields of new coronary pneumonia vaccine, diagnosis and treatment, etc. Innovation and patent examination were exchanged and shared.
The "Patent Landscape Report on Vaccines and Therapeutics Related to COVID-19", prepared by WIPO, is the organization's first report to analyze patent activity related to COVID-19 to study technological innovation trends related to the fight against the pandemic.
The report pointed out that in the 21 months after the outbreak began, 49 patent offices around the world received nearly 5,300 patent applications related to COVID-19, including nearly 1,500 applications related to treatments and more than 400 applications related to vaccines.
Among them, universities and scientific research institutions are the most active in vaccine-related applications.
According to the report, China is the largest source of patent applications related to COVID-19 vaccines and treatments.
As of September 2021, 276 vaccine-related patent applications have been filed in the same family from China, and Chinese applicants have also applied for 887 patents for COVID-19 treatments.
In terms of specific research and development, according to WHO data, as of October 2021, China has a total of 34 new coronary pneumonia vaccines under development, of which 23 have entered the clinical trial stage, ranking second in the world in total.
This shows that China is in the global "first phalanx" in the innovation of new coronary pneumonia vaccines and treatments.
The report also pointed out that major global intellectual property institutions, including the State Intellectual Property Office of China, have opened up green channels for COVID-19-related applications and accelerated the review process to varying degrees, reflecting the efforts of the global intellectual property system to respond to the challenges of the epidemic.